UC-II (Undenatured Type II Collagen) — Research Profile

UC-II is a branded undenatured (native) type II collagen studied at a low 40 mg daily dose for knee-joint outcomes. Hydrolyzed collagen is processed into peptides and is usually used at gram-level doses. They are not interchangeable: UC-II has a proposed oral-tolerance mechanism, while hydrolyzed collagen is studied as a peptide/amino-acid source.

No controlled trial has compared UC-II with food versus on an empty stomach, so an empty-stomach advantage has not been established. The human efficacy studies used 40 mg once daily. Use a consistent daily schedule and follow the specific product directions unless a clinician gives you different instructions.

UC-II was tested head-to-head against glucosamine plus chondroitin, not as an add-on to that combination. No controlled study has established extra benefit from combining them. There is also no trial evidence that they must be separated by meal timing, so treat any stacking benefit as unproven rather than assumed.

The only clinically validated form is low-dose undenatured (native) type II collagen at 40 mg once daily. Its proposed mechanism, inducing oral tolerance in gut-associated immune tissue, requires the collagen to remain undenatured, which is the opposite of high-gram hydrolyzed collagen peptides that are broken down for absorption and act differently. No higher-dose or hydrolyzed version has been shown to outperform standard 40 mg UC-II for joint outcomes.

In knee osteoarthritis, 40 mg/day reduced total WOMAC pain, stiffness, and physical-function scores versus placebo over 180 days and outperformed glucosamine plus chondroitin. In healthy adults with activity-related knee discomfort, it improved knee extension and let them exercise longer before pain by day 120, and increased knee flexion and extension range of motion at 24 weeks. The evidence centers on knee joint comfort and mobility, not skin, hair, or general collagen-building claims.

Every human efficacy trial used 40 mg once daily, both for knee osteoarthritis and for exercise-related joint discomfort. No higher intake has been shown to add benefit, and this deliberately low dose reflects an immune-tolerance mechanism rather than a more-is-better model. Stick to the studied 40 mg rather than scaling up.

No trial has compared morning versus evening or with-food versus empty-stomach dosing, so no optimal time has been demonstrated. All studies simply gave a single 40 mg dose once daily, and that is the pattern with actual evidence behind it. Pick a fixed daily time you will reliably keep.

Across controlled trials of 40 mg/day for up to 180 days, no product-related adverse events were reported and tolerability matched placebo. Mild digestive complaints can occur with any oral supplement, but they were not more frequent than placebo in these studies. The trial record shows no distinctive or dose-limiting side effect for UC-II.

No specific drug interactions have been formally studied or documented for UC-II. Because its proposed mechanism involves modulating the gut immune response, a theoretical overlap with immunosuppressant therapy is plausible but has never been tested; trials studied osteoarthritis patients and healthy adults rather than that population. If you take immune-modulating drugs, treat the interaction as unstudied rather than assumed safe.

The groups actually studied are adults with knee osteoarthritis and otherwise healthy, active people who get exercise-related knee discomfort or stiffness. It has not been tested in children, in pregnancy, or for joints other than the knee, so benefit outside knee comfort and mobility is unestablished. It is a targeted joint option, not a general collagen or skin supplement.

UC-II trials measured outcomes at fixed endpoints rather than week by week, so onset isn't precisely mapped, but the response is gradual over months, not days. In knee osteoarthritis, WOMAC pain, stiffness, and physical-function scores improved significantly versus placebo at day 180; a separate trial without a placebo arm showed a 33% WOMAC reduction from baseline by day 90 (versus 14% for glucosamine plus chondroitin). In active adults with exercise-related knee discomfort, longer pain-free exercise and better knee extension appeared by day 120, and range-of-motion gains by 24 weeks. Expect to give it roughly 2 to 6 months before judging benefit.

The longest controlled human trials ran 180 days in knee osteoarthritis patients and 24 weeks in active adults, both at 40 mg daily, with no product-related adverse events and safety outcomes no different from placebo. Beyond about 6 months, controlled human safety data have not been published, so open-ended daily use is reasonable but not formally validated. Nothing in the trial record points to a cumulative safety concern at the 40 mg dose.

No tolerable upper limit has been set, and every human efficacy trial used just 40 mg per day, so there is no evidence that taking more helps. In animal toxicology, the acute oral LD50 exceeded 5000 mg/kg, UC-II was non-mutagenic in Ames and mouse-lymphoma assays, and a 90-day subchronic study found no significant organ, hematology, or blood-chemistry changes. Because its mechanism relies on a low oral dose rather than saturating the body with collagen, exceeding 40 mg offers no proven advantage.

In clinical trials UC-II was tested head-to-head against glucosamine plus chondroitin (1500 mg and 1200 mg daily), not stacked with it, and produced larger WOMAC and pain improvements than that combination. No controlled study has evaluated UC-II taken together with glucosamine, chondroitin, or other joint agents, so any additive benefit from combining them is unproven. There is likewise no documented harm from taking it alongside them.

Look specifically for undenatured or native type II collagen (the trademarked UC-II ingredient), because its activity depends on the collagen's intact triple-helix epitope, which the heat and acid processing used to make hydrolyzed collagen destroys. Products should supply 40 mg per day, the exact dose used in every efficacy trial. A label reading hydrolyzed, denatured, or gram-dose type II collagen is a different ingredient and does not carry this evidence.